发明名称 ''terapias de combinações de domínio extracelular fgfr1
摘要 Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.
申请公布号 BR112013012041(A2) 申请公布日期 2016.11.08
申请号 BR20131112041 申请日期 2011.11.14
申请人 FIVE PRIME THERAPEUTICS, INC 发明人 LI LONG;THOMAS BRENNAN
分类号 A61K31/475;A61K31/337;A61K31/4745;A61K31/513;A61K31/519;A61K31/555;A61K31/704;A61K31/7048;A61K33/24;A61K38/17;A61K38/18;A61K39/395;A61K45/06;A61P35/00;C07K19/00 主分类号 A61K31/475
代理机构 代理人
主权项
地址